From 2013 to 2023, the import of medicaments mixed together for therapeutic use to China has shown fluctuations. Despite some years of decline, the overall trend in the decade has been upward. In 2023, the value stood at 341.99 million USD, indicating a modest upsurge with a 2.53% year-on-year increase from 2022. Over the past two years, the import value grew, but more moderately compared to the 13.05% increase in 2021. The 5-year CAGR leading up to 2023 is 2.12%, showing steady growth albeit at a slower pace.
Forecasts suggest that from 2024 to 2028, the import value will continue to grow, albeit more gradually, with a forecasted 5-year CAGR of 1.7%. This translates to a cumulative growth of about 8.8% over the forecast period.
Future trends to watch for include:
• Growing demand for therapeutic medicaments in response to an aging population.
• Potential regulatory changes influencing import dynamics.
• Technological advancements and their impact on pharmaceutical trade.
• Economic factors affecting purchasing power and import capabilities.
